<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078010</url>
  </required_header>
  <id_info>
    <org_study_id>17-097</org_study_id>
    <nct_id>NCT03078010</nct_id>
  </id_info>
  <brief_title>Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant</brief_title>
  <official_title>Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how different antibiotics affect the community of
      friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these
      friendly bacteria are not harmful and they help with normal bodily functions such as
      digestion. When these bacteria are absent, several complications may occur, such as
      infections with harmful bacteria or other inflammatory reactions, that can complicate the
      stem cell transplant course. Treatment with antibiotics or chemotherapy is known to kill off
      these friendly bacteria. In this study we compare the effects of different antibiotics on the
      community of friendly bacteria in the gut.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized open-label phase II study to assess the association between antibiotic treatment strategies and the change in the relative abundance of Clostridiales.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of fold-change in Clostridiales abundance</measure>
    <time_frame>7 +/- 2 days after initiation of piperacillin-tazobactam or cefepime</time_frame>
    <description>Fold change will be assessed 7 +/- 2 days after initiating antibiotic treatment for febrile neutropenia and will be compared to the pre-treatment specimen. Pre-treatment stool specimen will be collected between the time of enrollment Patients will be enrolled and infusion of allografts or first episode of neutropenic fever, whichever occurs first.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Intestinal Microbiome</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Piperacillin-tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cefepime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam</intervention_name>
    <description>piperacillin-tazobactam (4.5 gm IV q 6 hrs)</description>
    <arm_group_label>Piperacillin-tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <description>(2 gm IV q 8 hrs)</description>
    <arm_group_label>cefepime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with any hematologic malignancy undergoing either an unmodified allogeneic
             HCT or a double umbilical cord blood transplant with or without the infusion of T-cell
             depleted HLA-haploidentical peripheral blood stem cells.

          -  Patients undergoing an umodified transplant must have a related or unrelated marrow or
             peripheral blood stem cell (PBSC) donor as follows:

        A. Sibling donor must be a 6/6 match for HLA-A and -B at intermediate (or higher)
        resolution, and HLA-DRB1 at high resolution using DNA-based typing B. Unrelated donor must
        be an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing.

        Exclusion Criteria:

          -  Patients with severe allergies to piperacillin-tazobactam or cefepime or aztreonam.
             Severe reactions include anaphylaxis and Stevens-Johnson syndrome (SJS)/toxic
             epidermal necrolysis (TEN).

          -  Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime or aztreonam
             can be evaluated by an Allergy/Immunology specialist, after which they may become
             eligible by a consensus of the treating physician, trial investigator and and the
             Allery

          -  Prolonged antibiotic treatment ( ≥10 days, within 3 weeks of enrollment) as prevention
             or suppression of an ongoing infection, where treatment involves gut-perturbing anti
             anaerobic antibiotics

          -  Patients known to be colonized with multi-drug resistant organisms or with history of
             infection with multi-drug resistant organisms. Patients with history of infection with
             extended-spectrum beta-lactamase producing organism.

          -  Febrile patients

          -  Patients with estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m^2

          -  Patients receiving post-transplant cyclophosphamide as GVHD prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <phone>212-639-2860</phone>
    <email>gyurkocb@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Seo, MD</last_name>
    <phone>212-639-3151</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boglarka Gyurkocza, MD</last_name>
      <phone>212-639-2860</phone>
    </contact>
    <contact_backup>
      <last_name>Susan Seo, MD</last_name>
      <phone>212-639-3151</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic</keyword>
  <keyword>piperacillin-tazobactam</keyword>
  <keyword>cefepime</keyword>
  <keyword>aztreonam</keyword>
  <keyword>17-097</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

